Previous studies have demonstrated that BRAF/MEK inhibition with dabrafenib and trametinib in BRAFV600E mutated ATC can result in substantial tumor shrinkage, thereby increasing the likelihood of achieving complete (R0/R1) resections (14, 15). Here, BRAF is linked to neoplasm.